Recordati Rare Diseases
Recordati Rare Diseases is a specialty pharmaceutical business unit within publicly traded Recordati S.p.A. (XMIL: REC) that develops, manufactures, and distributes orphan drugs across endocrinology, oncology-hematology, and metabolic rare disease franchises to patients and healthcare professionals in approximately 150 countries worldwide.
- Company typePublic
- Founded1926
- HeadquartersMilan, Italy
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Recordati Rare Diseases does
Recordati Rare Diseases is a specialty pharmaceutical business unit within the publicly traded Recordati S.p.A. group (XMIL: REC), dedicated to developing, manufacturing, and commercialising orphan drugs for rare diseases across three core therapeutic franchises: endocrinology (Cushing's syndrome, acromegaly — including Isturisa and Signifor LAR), oncology-hematology (Castleman disease via Sylvant, cold agglutinin disease via Enjaymo, neuroblastoma via Qarziba, cutaneous T-cell lymphoma via Ledaga), and metabolic disorders (cystinosis, homocystinuria, Wilson's disease, hyperammonemia, phenylketonuria, acute hepatic porphyrias). The unit originated from Recordati's 2007 acquisition of Orphan Europe and was further expanded via the 2022 acquisition of EUSA Pharma and the 2024 acquisition of global rights to Enjaymo from Sanofi. It serves patients and healthcare professionals across approximately 150 countries, distributing through a dedicated 1,600 sq. m. specialist packaging and distribution centre in Paris that handles over 27,000 orders annually to 60+ countries, complemented by hospital pharmacies, specialty pharmacy networks, and direct country operations in the US, Canada, Brazil, Mexico, Colombia, Japan, China, South Korea, Australia, and across Europe.
The business model is anchored in pharmaceutical product sales (one-time licensing of in-house and acquired products) supplemented by licensing and supply agreements (e.g., Vazkepa from Amarin, 2025). Pricing is managed through national health technology assessment bodies and hospital/specialty pharmacy channels rather than direct list pricing, reflecting the orphan-drug reimbursement environment. Go-to-market combines enterprise field sales (highly trained Orphan Drug Specialists engaging healthcare professionals, payers, and regulators across the full patient-management lifecycle) with direct-to-patient advocacy through partnerships with more than a dozen patient organisations including Global Genes, NUCDF, CORD, MetabERN, and Acromegaly Canada. Competitive advantages rest on regulatory expertise in orphan drug designations and named-patient programs, dedicated rare-disease logistics infrastructure, and a 100-year parent-group brand heritage. The Paris distribution centre, combined with the manufacturing footprint of the broader Recordati Group (two chemical plants and seven manufacturing sites worldwide), provides capital-intensive operational depth that smaller competitors cannot easily replicate.
Recordati Rare Diseases firmographics
Firmographics- Name
- Recordati Rare Diseases
- Legal name
- Recordati AG, Rare Diseases Branch
- Website
- https://recordatirarediseases.com
- Company type
- Public
- Founded year
- 1926
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Recordati Rare Diseases is a specialty pharmaceutical business unit within publicly traded Recordati S.p.A. (XMIL: REC) that develops, manufactures, and distributes orphan drugs across endocrinology, oncology-hematology, and metabolic rare disease franchises to patients and healthcare professionals in approximately 150 countries worldwide.
- Ownership category
- akta.pro rank
Recordati Rare Diseases industry classification
Industry- Product category
- Rare Disease Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)
- akta.pro secondary industries
- Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where Recordati Rare Diseases is headquartered
LocationHeadquarters
- HQ city
- Milan
- HQ country
- Italy
- HQ region
- Europe
Offices4 records
Markets served
Recordati Rare Diseases business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel
Revenue model
- Pharmaceutical product sales: Sale of specialty and orphan drugs for rare diseases including treatments for endocrinology, oncology-hematology, and metabolic conditions. Products are distributed globally to hospitals, specialty pharmacies, and directly to patients.
- Licensing and supply agreements: Acquisition and licensing of global rights to treatments. Recent agreements include Enjaymo from Sanofi (2024) and Vazkepa from Amarin (2025)
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Orphan drug specialty pharmaceuticals |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Recordati Rare Diseases product offering
Product offeringCore offering
Recordati Rare Diseases develops, manufactures, and commercializes pharmaceutical products (orphan drugs) for the treatment of rare diseases. Its portfolio spans three core therapeutic areas—endocrinology, oncology-hematology, and metabolic disorders—and includes more than 20 branded specialty medicines (e.g., Sylvant, Isturisa, Signifor, Cystagon, Carbaglu, Enjaymo) sold globally to hospitals, specialty pharmacies, and through named-patient programs across roughly 60 countries.
Product overview
Recordati Rare Diseases is a pharmaceutical company specializing in orphan and rare disease medicines. The company operates a portfolio of specialty pharmaceutical products organized across three core therapeutic areas: Endocrinology (including Cushing's syndrome and acromegaly treatments like ISTURISA and SIGNIFOR), Oncology-Hematology (including treatments for Castleman disease, cold agglutinin disease, cutaneous T-cell lymphoma, neuroblastoma, and rare cancers), and Metabolic disorders (including treatments for cystinosis, homocystinuria, acute hepatic porphyrias, hyperammonemia, Wilson's disease, and phenylketonuria). The product portfolio includes both internally developed and acquired brands commercialized across approximately 60 countries worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- CARBAGLU (carglumic acid)
Quantifiable outcome
- Presence in ~150 countries serving rare disease patients globally
- +2 more outcomes
Companies that use Recordati Rare Diseases
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles4 records
Recordati Rare Diseases technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Recordati Rare Diseases partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Global GenescoreLeading rare disease advocacy organization whose mission is to build awareness, educate the global community, and provide critical connections and resources that equip advocates to become activists for their disease. Recordati provides support and engagement through this partnership.
- National Urea Cycle Disorders Foundation (NUCDF)coreDedicated to the identification, treatment and cure of urea cycle disorders. Partnership supports patient education and awareness for hyperammonemia and related metabolic conditions.
- Canadian Organization for Rare Disorders (CORD)coreCanada's national network for organizations representing all those with rare disorders. CORD provides strong common voice to advocate for health policy and healthcare system that works for rare disease patients.
- The Garrod AssociationminorCanadian permanent national body for coordination of management of inherited metabolic disorders.
- International Porphyria NetworkcoreWorldwide network providing support and information for patients with porphyria and their families, supporting acute hepatic porphyria treatment awareness.
- Cystinosis Network EuropecorePatient organization network supporting nephropathic cystinosis awareness and treatment access across Europe.
- E-HOD (European Network for Homocystinurias)minorEuropean Network and Registry for Homocystinurias and Methylation Defects supporting diagnosis and treatment awareness.
- MetabERN (European Reference Network)coreEuropean Reference Network for Hereditary Metabolic Disorders supporting rare metabolic disease communities.
- Acromegaly CanadaminorNot-for-profit organization established in 2019 to bring together Canadians whose lives touched by acromegaly, raising awareness through education and providing support network.
- Lymphoma CanadaminorCommunity organization helping people talk about and cope with lymphoma, the fifth most common cancer in Canada.
- Recordati Rare Diseases FoundationcoreNot-for-profit corporate foundation operating independently from business, organizing training on rare diseases to improve diagnosis and spread therapeutic knowledge. Has delivered over 75 courses to over 3,000 healthcare professionals.
- Arrigo PrizeminorInternational recognition prize established in 2000 in memory of Arrigo Recordati to promote scientific research, currently dedicated to paediatric oncology (sarcomas).
- Scientific societies partnershipscoreStrong and unique partnership with international scientific societies supporting rare disease research, education, and treatment advancement.
Scale indicators6 records
Recent moves12 records
Expansion highlights6 records
Recordati Rare Diseases competitors and assessment
Company assessmentBroad incumbents
- Sanofi (Genzyme Rare Diseases): Global pharmaceutical company with established rare disease unit (Genzyme) in rare hematology, lysosomal storage disorders, and oncology. Recently divested Enjaymo to Recordati; ongoing competitor in adjacent rare hematology indications.
- Novartis (Rare Disease franchises): Global pharmaceutical major with multiple rare disease assets across hematology and oncology. Senior Recordati Rare Diseases leadership previously held roles at Novartis Oncology, indicating direct talent overlap and competitive landscape.
- Amgen: Global biotechnology company with rare disease presence including hematology and metabolic franchises. Recently partnered with Recordati Rare Diseases via Vazkepa licensing deal (2025), reflecting both competitive and partnering dynamics.
- Takeda (Shire Rare Disease): Global pharmaceutical major with substantial rare disease franchise following Shire acquisition. Competes in hereditary angioedema, rare hematology, and metabolic diseases; larger portfolio and broader commercial reach than Recordati Rare Diseases.
Direct peers
- Alexion (AstraZeneca Rare Disease): Pure-play rare disease unit within AstraZeneca specializing in hematology, neurology, and metabolic disorders. Competes head-to-head with Recordati Rare Diseases in cold agglutinin disease (Enjaymo vs. Alexion assets) and similar ultra-rare hematology indications.
- Vertex Pharmaceuticals: Rare disease-focused commercial-stage company with strong cystic fibrosis franchise overlapping with Recordati Rare Diseases' metabolic portfolio (VEDROP for cystic fibrosis-related vitamin E deficiency).
- Sobi (Swedish Orphan Biovitrum): Dedicated rare disease pharmaceutical company with overlapping focus in hematology, immunology, and specialty metabolic conditions. Most directly comparable European orphan-drug peer with similar go-to-market model and patient-centric distribution approach.
- Ultragenyx Pharmaceutical: Clinical and commercial rare disease company developing and commercializing therapies for rare and ultra-rare genetic diseases — directly comparable patient populations and regulatory pathways.
- BioMarin Pharmaceutical: Specialty biotech focused exclusively on rare diseases across endocrinology, hematology, and inherited metabolic disorders. Highly comparable therapeutic mix and reliance on orphan drug exclusivity economics.
Regional players
- Chiesi Farmaceutici: Italian-headquartered specialty pharmaceutical company with rare disease focus (Chiesi Global Rare Diseases). Geographic overlap in EMEA and comparable therapeutic mix in inherited metabolic disorders. Multiple Recordati Rare Diseases leaders previously held roles at Chiesi.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Recordati Rare Diseases social profiles
Digital presenceRecordati Rare Diseases financial estimates
Financial estimateRevenue estimate
Valuation estimate
Recordati Rare Diseases leadership team
Management profileNumber of profiles
Profiles13 records
Recordati Rare Diseases subsidiaries and ownership
Company hierarchySubsidiaries2 records
Recordati Rare Diseases funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Recordati Rare Diseases M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Recordati Rare Diseases
What does Recordati Rare Diseases do?
Recordati Rare Diseases develops, manufactures, and commercializes pharmaceutical products (orphan drugs) for the treatment of rare diseases. Its portfolio spans three core therapeutic areas—endocrinology, oncology-hematology, and metabolic disorders—and includes more than 20 branded specialty medicines (e.g., Sylvant, Isturisa, Signifor, Cystagon, Carbaglu, Enjaymo) sold globally to hospitals, specialty pharmacies, and through named-patient programs across roughly 60 countries.
Is Recordati Rare Diseases a public or private company?
Recordati Rare Diseases is a public company. It is classified as corporate owned and is currently operating.
When was Recordati Rare Diseases founded?
Recordati Rare Diseases was founded in 1926. It employs 251 to 500 people.
Where is Recordati Rare Diseases based?
Recordati Rare Diseases is headquartered in Milan, Italy, in the Europe region.
How does Recordati Rare Diseases make money?
Two revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are licensing and supply agreements.
Who are Recordati Rare Diseases's main competitors?
Broad incumbents on record are Sanofi (Genzyme Rare Diseases), Novartis (Rare Disease franchises), Amgen and Takeda (Shire Rare Disease). Direct peers are Alexion (AstraZeneca Rare Disease), Vertex Pharmaceuticals, Sobi (Swedish Orphan Biovitrum), Ultragenyx Pharmaceutical and BioMarin Pharmaceutical. Chiesi Farmaceutici is listed as a regional player.
Does Recordati Rare Diseases have an API?
No public API is recorded for Recordati Rare Diseases.
What industry is Recordati Rare Diseases in?
Recordati Rare Diseases's product category is Rare Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies, with a secondary code of HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies. Its NAICS code is 3254 and its SIC code is 2834.